Celularity (NASDAQ:CELU) Earns Moderate Buy Rating from Analysts at WBB Securities

Key Points

• WBB Securities has initiated coverage on Celularity (NASDAQ:CELU) with a "speculative buy" rating and a price target of $6.00, suggesting a potential upside of 60% from the current trading price.
• Despite WBB's positive outlook, Wall Street Zen recently downgraded Celularity to a "sell" rating, indicating mixed sentiment among analysts.
• Institutional investors have shown interest in Celularity, with Bank of America Corp DE significantly increasing its position by 1,538.1% in the second quarter of this year.

Analysts at WBB Securities started coverage on shares of Celularity (NASDAQ:CELU - Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a "moderate buy" rating and a $6.00 price target on the stock. WBB Securities' price target would indicate a potential upside of 58.31% from the company's previous close.

Separately, Wall Street Zen raised shares of Celularity to a "sell" rating in a research report on Saturday, August 2nd.

Celularity Trading Up 5.0%

Shares of NASDAQ:CELU traded up $0.18 during mid-day trading on Monday, reaching $3.79. 48,756 shares of the company were exchanged, compared to its average volume of 84,981. The company has a debt-to-equity ratio of 4.07, a current ratio of 0.38 and a quick ratio of 0.28. The firm has a market cap of $90.77 million, a price-to-earnings ratio of -1.43 and a beta of 0.79. The firm's 50-day simple moving average is $2.70 and its 200 day simple moving average is $2.09. Celularity has a 1 year low of $1.00 and a 1 year high of $5.22.

Institutional Investors Weigh In On Celularity

Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new stake in Celularity during the 4th quarter worth approximately $93,000. Bank of America Corp DE raised its holdings in Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after acquiring an additional 35,023 shares in the last quarter. XTX Topco Ltd raised its holdings in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after acquiring an additional 11,057 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Celularity in the first quarter valued at approximately $34,000. Finally, Valmark Advisers Inc. acquired a new stake in Celularity in the second quarter valued at approximately $98,000. 19.02% of the stock is currently owned by institutional investors and hedge funds.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.